Long-Term Efficacy and Safety of Brentuximab Vedotin in Hodgkin Lymphoma Patients

Long-Term Efficacy and Safety of Brentuximab Vedotin in Hodgkin Lymphoma Patients

Improving safety and efficacy with brentuximab vedotin, nivolumab and AD for advanced stage cHL.Подробнее

Improving safety and efficacy with brentuximab vedotin, nivolumab and AD for advanced stage cHL.

Real-world efficacy of brentuximab vedotin as consolidation therapy in patients with HLПодробнее

Real-world efficacy of brentuximab vedotin as consolidation therapy in patients with HL

Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?Подробнее

Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?

How effective is nivolumab + brentuximab vedotin as a consolidation therapy for Hodgkin lymphoma?Подробнее

How effective is nivolumab + brentuximab vedotin as a consolidation therapy for Hodgkin lymphoma?

Current indications for the use of brentuximab vedotin in Hodgkin lymphomaПодробнее

Current indications for the use of brentuximab vedotin in Hodgkin lymphoma

Dr. Yasenchak on the Safety Profile of Brentuximab Vedotin/Nivolumab in Hodgkin LymphomaПодробнее

Dr. Yasenchak on the Safety Profile of Brentuximab Vedotin/Nivolumab in Hodgkin Lymphoma

Radhakrishnan Ramchandren, MD, provides perspective on the safety & efficacy of brentuximab vedotinПодробнее

Radhakrishnan Ramchandren, MD, provides perspective on the safety & efficacy of brentuximab vedotin

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphomaПодробнее

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma

Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trialПодробнее

Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial

First Line Treatment of CLLПодробнее

First Line Treatment of CLL

Current and emerging treatment options for Hodgkin lymphomaПодробнее

Current and emerging treatment options for Hodgkin lymphoma

Acceptable Safety Observed With Frontline Brentuximab Vedotin Combo in HLПодробнее

Acceptable Safety Observed With Frontline Brentuximab Vedotin Combo in HL

Hodgkin Lymphoma: Using Brentuximab Vedotin FrontlineПодробнее

Hodgkin Lymphoma: Using Brentuximab Vedotin Frontline

The real-world efficacy of brentuximab vedotin consolidation post-autoSCT in R/R HLПодробнее

The real-world efficacy of brentuximab vedotin consolidation post-autoSCT in R/R HL

N-AVD demonstrates superior efficacy and safety to Bv-AVD in older patients with advanced-stage HLПодробнее

N-AVD demonstrates superior efficacy and safety to Bv-AVD in older patients with advanced-stage HL

Peripheral T-Cell Lymphoma Treatment Regimen Still Safe and Efficacious at 5-Year Follow-UpПодробнее

Peripheral T-Cell Lymphoma Treatment Regimen Still Safe and Efficacious at 5-Year Follow-Up

An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HLПодробнее

An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HL

Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphomaПодробнее

Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma

ECHELON-2: brentuximab vedotin and CHP for CD30-positive T-cell lymphomasПодробнее

ECHELON-2: brentuximab vedotin and CHP for CD30-positive T-cell lymphomas

Brentuximab vedotin combined with nivolumab for Hodgkin lymphomaПодробнее

Brentuximab vedotin combined with nivolumab for Hodgkin lymphoma